虽然TScan Therapeutics报告了2024年第一季度的收入下降, 但其主要产品TSC-100和TSC-101正在I期临床试验中, TScan Therapeutics reports Q1 2024 revenue decline, but lead products TSC-100 and TSC-101 are in Phase I clinical trials, and several analysts have issued "buy"
生物制药公司TSCAN治疗技术(TCRX)侧重于T细胞受体为治疗癌症而设计的T细胞疗法。 Biopharmaceutical company TScan Therapeutics (TCRX) focuses on T-cell receptor engineered T cell therapies for cancer treatment. 在上一季度分析师的评级中，4个为“看涨”，1个为“有点看涨”。 Among analysts' ratings over the last quarter, 4 are "bullish" and 1 is "somewhat bullish." 12个月价格目标平均为12.6美元,估计高低分别为15美元和100美元。 The 12-month price targets averaging $12.6 with high and low estimates at $15.00 and $10.00, respectively. 该公司的收入在2024年第1季度下降了91.68%,但净利润高达5 325.44%,低于行业标准。 The company's revenue declined by -91.68% in Q1 2024, but it has a strong net margin of -5,325.44% and ROE/ROA below industry standards. TCRX的铅产品TSC-100和TSC-101正处于第一阶段临床试验阶段。 TCRX's lead products, TSC-100 and TSC-101, are in Phase I clinical trials. 一些分析家发表了“买入”评级,目标价格从10.00美元到15.00美元不等。 Several analysts have issued "buy" ratings with target prices ranging from $10.00 to $15.00.